RINVOQ LQ Drug Patent Profile
✉ Email this page to a colleague
When do Rinvoq Lq patents expire, and what generic alternatives are available?
Rinvoq Lq is a drug marketed by Abbvie and is included in one NDA. There are ten patents protecting this drug.
This drug has one hundred and seventy-six patent family members in forty-one countries.
The generic ingredient in RINVOQ LQ is upadacitinib. One supplier is listed for this compound. Additional details are available on the upadacitinib profile page.
DrugPatentWatch® Generic Entry Outlook for Rinvoq Lq
Rinvoq Lq was eligible for patent challenges on August 16, 2023.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 17, 2036. This may change due to patent challenges or generic licensing.
There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RINVOQ LQ?
- What are the global sales for RINVOQ LQ?
- What is Average Wholesale Price for RINVOQ LQ?
Summary for RINVOQ LQ
International Patents: | 176 |
US Patents: | 10 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 39 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for RINVOQ LQ |
DailyMed Link: | RINVOQ LQ at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for RINVOQ LQ
Generic Entry Date for RINVOQ LQ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for RINVOQ LQ
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Berinstein, Jeffrey | Phase 4 |
The Ottawa Hospital | Phase 4 |
Ottawa Hospital Research Institute | Phase 4 |
Pharmacology for RINVOQ LQ
Drug Class | Janus Kinase Inhibitor |
Mechanism of Action | Janus Kinase Inhibitors |
US Patents and Regulatory Information for RINVOQ LQ
RINVOQ LQ is protected by eleven US patents and three FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of RINVOQ LQ is ⤷ Subscribe.
This potential generic entry date is based on patent 9,951,080.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | RINVOQ LQ | upadacitinib | SOLUTION;ORAL | 218347-001 | Apr 26, 2024 | RX | Yes | Yes | 8,962,629 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Abbvie | RINVOQ LQ | upadacitinib | SOLUTION;ORAL | 218347-001 | Apr 26, 2024 | RX | Yes | Yes | RE47221 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Abbvie | RINVOQ LQ | upadacitinib | SOLUTION;ORAL | 218347-001 | Apr 26, 2024 | RX | Yes | Yes | 10,981,923 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Abbvie | RINVOQ LQ | upadacitinib | SOLUTION;ORAL | 218347-001 | Apr 26, 2024 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Abbvie | RINVOQ LQ | upadacitinib | SOLUTION;ORAL | 218347-001 | Apr 26, 2024 | RX | Yes | Yes | 11,718,627 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for RINVOQ LQ
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
AbbVie Deutschland GmbH & Co. KG | Rinvoq | upadacitinib | EMEA/H/C/004760 Rheumatoid arthritisRINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.Psoriatic arthritisRINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.Atopic dermatitisRINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Ulcerative colitisRINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Crohn’s diseaseRINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. |
Authorised | no | no | no | 2019-12-16 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for RINVOQ LQ
When does loss-of-exclusivity occur for RINVOQ LQ?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 16340167
Estimated Expiration: ⤷ Subscribe
Patent: 20359635
Estimated Expiration: ⤷ Subscribe
Patent: 21236570
Estimated Expiration: ⤷ Subscribe
Patent: 23251492
Estimated Expiration: ⤷ Subscribe
Brazil
Patent: 2018007677
Estimated Expiration: ⤷ Subscribe
Patent: 2022005765
Estimated Expiration: ⤷ Subscribe
Patent: 2022024925
Estimated Expiration: ⤷ Subscribe
Canada
Patent: 02220
Estimated Expiration: ⤷ Subscribe
Patent: 23260
Estimated Expiration: ⤷ Subscribe
Patent: 56170
Estimated Expiration: ⤷ Subscribe
China
Patent: 8368121
Estimated Expiration: ⤷ Subscribe
Patent: 4929227
Estimated Expiration: ⤷ Subscribe
Patent: 6270645
Estimated Expiration: ⤷ Subscribe
Patent: 6270646
Estimated Expiration: ⤷ Subscribe
Patent: 6284011
Estimated Expiration: ⤷ Subscribe
European Patent Office
Patent: 62455
Estimated Expiration: ⤷ Subscribe
Patent: 37686
Estimated Expiration: ⤷ Subscribe
Patent: 19503
Estimated Expiration: ⤷ Subscribe
Hong Kong
Patent: 63380
Estimated Expiration: ⤷ Subscribe
Israel
Patent: 8654
Estimated Expiration: ⤷ Subscribe
Patent: 3531
Estimated Expiration: ⤷ Subscribe
Japan
Patent: 70775
Estimated Expiration: ⤷ Subscribe
Patent: 58317
Estimated Expiration: ⤷ Subscribe
Patent: 19501865
Estimated Expiration: ⤷ Subscribe
Patent: 21020902
Estimated Expiration: ⤷ Subscribe
Patent: 22107001
Estimated Expiration: ⤷ Subscribe
Patent: 22549379
Estimated Expiration: ⤷ Subscribe
Patent: 23113917
Estimated Expiration: ⤷ Subscribe
Mexico
Patent: 18004605
Estimated Expiration: ⤷ Subscribe
Patent: 21013812
Estimated Expiration: ⤷ Subscribe
Patent: 22003872
Estimated Expiration: ⤷ Subscribe
Russian Federation
Patent: 18117889
Estimated Expiration: ⤷ Subscribe
Singapore
Patent: 201913986Y
Estimated Expiration: ⤷ Subscribe
Patent: 201913987U
Estimated Expiration: ⤷ Subscribe
Patent: 201913989Q
Estimated Expiration: ⤷ Subscribe
Patent: 201913990R
Estimated Expiration: ⤷ Subscribe
Patent: 201913993Q
Estimated Expiration: ⤷ Subscribe
Patent: 201913997W
Estimated Expiration: ⤷ Subscribe
Patent: 201913999P
Estimated Expiration: ⤷ Subscribe
Patent: 201802990R
Estimated Expiration: ⤷ Subscribe
South Korea
Patent: 180081523
Estimated Expiration: ⤷ Subscribe
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering RINVOQ LQ around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Mexico | 2022003872 | ⤷ Subscribe | |
Hungary | E028347 | ⤷ Subscribe | |
Singapore | 10201913993Q | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | ⤷ Subscribe |
New Zealand | 600161 | Novel tricyclic compounds | ⤷ Subscribe |
World Intellectual Property Organization (WIPO) | 2011068881 | ⤷ Subscribe | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for RINVOQ LQ
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2506716 | C20200006 00317 | Estonia | ⤷ Subscribe | PRODUCT NAME: UPADATSITINIIB;REG NO/DATE: EU/1/19/1404; 18.12.2019 |
2506716 | 20C1009 | France | ⤷ Subscribe | PRODUCT NAME: UPADACITINIB OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/19/1404 20191218 |
2506716 | 2020C/505 | Belgium | ⤷ Subscribe | PRODUCT NAME: UPADACITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/19/1404 20191218 |
2506716 | SPC/GB20/012 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: UPADACITINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/19/1404(FOR NI) 20191218; UK PLGB41042/0042 20191218; UK PLGB41042/0087 20191218 |
2506716 | 301035 | Netherlands | ⤷ Subscribe | PRODUCT NAME: UPADACITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/19/1404 20191218 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
RINVOQ LQ Market Analysis and Financial Projection Experimental
More… ↓